box10.gif (1299 bytes)

 

 

 

 

 

 

Medical devices

Biosign supplies monitoring gear to pain study

TORONTO – Biosign Technologies Inc. has announced the commercial launch of its UFIT system in the medical research market. Under the terms of a purchase order from Algogene Pain Genetics, Biosign will supply UFIT devices and online test, measurement and analysis services to a study on chronic pain.

The study is a collaboration between The University of Toronto Centre for the Study of Pain, The Centre for International Health, and Algogene Pain Genetics.

The collaboration is primarily aimed at identifying pain mechanisms and genetic targets for developing better pain medication.

Biosign’s technology will be used to assess blood pressure, blood glucose, autonomic nervous system features, and other parameters in 4,500 amputees over one year.

“In spite of a rigorous search, we were unable to find another non-invasive measurement system that provides the kind of power and versatility required for studying the interplay between morbidities such as hypertension and diabetes associated with untreatable persistent pain”, said Dr. Ze’ev Seltzer, the study’s lead investigator, a professor of genetics at the Faculties of Dentistry and Medicine at the University of Toronto, who holds a Canada Research Chair in Pain Genetics.


About Biosign Technologies Inc.
Biosign provides technologies, products and initiatives to address critical problems in global healthcare. The focus is on monitoring health status, outcomes, and risk toward maximizing clinical awareness, readiness, and effectiveness. The thrust is on enabling autonomous medical care to optimize healthcare quality, access, and cost. The core technology expands virtual instrumentation with universal measurement and rapid knowledge formation to support service-oriented enterprising across global markets. Trademarked UFIT, the web-based technology powers several business lines in self-care, wellness, remote patient monitoring, and chronic disease evaluation and management. Key applications include intelligent systems for noninvasive monitoring of common health risks such as high blood pressure, high blood glucose, and adverse responses to medication. For more information on Biosign please visit http://www.biosign.com

Posted Aug. 13/09.

 

HOME - CURRENT ISSUE - ABOUT US - SUBSCRIBE - ADVERTISE - ARCHIVES - CONTACT US - EVENTS - LINKS